CHAPTER 1 INTRODUCTION
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Key findings
3.2.1 Top investment pockets
3.2.2 Top winning strategies
3.3 Porters five forces analysis
3.3.1 Bargaining power of buyers (High)
3.3.2 Bargaining power of suppliers (Low to Moderate)
3.3.3 Threat of new entrants (Low)
3.3.4 Threat of substitutes (High)
3.3.5 Intense competitive rivalry
3.4 Market dynamics
3.4.1 Drivers
3.4.1.1 Increasi in number of asthmatic and COPD patients worldwide
3.4.1.2 Increase in world ageing population
3.4.1.3 Technological advancement in the treatment of asthma and COPD drugs
3.4.1.4 Initiatives taken by various government associations to raise awareness about daignosis and management of asthma and COPD
3.4.1.5 Increasing number of products in the pipeline
3.4.2 Restraints
3.4.2.1 Stringent regulatory requirements for the approval and commercialization of asthma and COPD drugs
3.4.2.2 Asthma and COPD drugs show side effects
3.4.2.3 Asthma and COPD drug approval process is expensive and time-consuming
3.4.2.4 Patent expiry of asthma and COPD drugs
3.4.3 Opportunities
3.4.3.1 Inrtoduction of generic drugs of asthma and COPD drugs
3.5 Market share analysis, 2015
CHAPTER 4 GLOBAL ASTHMA AND COPD DRUGS MARKET, BY DISEASE
4.1 Overview
4.2 Asthma
4.2.1 Global prevalence
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.3 COPD
4.3.1 Global prevalence
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
CHAPTER 5 GLOBALASTHMA AND COPD DRUGS MARKET, BY MEDICATION CLASS
5.1 Overview
5.2 Combination Drugs
5.2.1 Market size and forecast
5.2.2 Seretide/Advair
5.2.3 Symbicort
5.2.4 Relvar/Breo Ellipta
5.2.5 Flutiform
5.2.6 Dulera
5.3 Leukotriene antagonists (LTA)
5.3.1 Market size and forecast
5.3.2 Singulair
5.4 Inhaled corticosteroids (ICS)
5.4.1 Market size and forecast
5.4.2 Qvar
5.4.3 Pulmicort
5.4.4 Aerospan
5.4.5 Flovent
5.5 Anticholinergics
5.5.1 Market size and forecast
5.5.2 Spiriva
5.6 Short acting beta agonists (SABA)
5.6.1 Market size and forecast
5.6.2 ProAir
5.6.3 Ventolin
5.7 Long acting beta agonists (LABA)
5.7.1 Market size and forecast
5.8 Others
5.8.1 Market size and forecast
CHAPTER 6 GLOBALASTHMA AND COPD DRUGS MARKET, BY GEOGRAPHY, 2015-2022
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
6.2.4 U.S.: market size and forecast
6.2.5 Canada market size and forecast
6.2.6 Mexico: market size and forecast
6.3 Europe
6.3.1 Key market trends
6.3.2 Key growth factors and opportunities
6.3.3 Germany: market size and forecast
6.3.4 France market size and forecast
6.3.5 UK: market size and forecast
6.3.6 Italy market size and forecast
6.3.7 Rest of Europe: market size and forecast
6.4 Asia-Pacific
6.4.1 Key market trends
6.4.2 Key growth factors and opportunities
6.4.3 Market size and forecast
6.4.4 Japan: market size and forecast
6.4.5 China market size and forecast
6.4.6 India: market size and forecast
6.4.7 Rest of Asia-Pacific market size and forecast
6.5 LAMEA
6.5.1 Key market trends
6.5.2 Key growth factors and opportunities
6.5.3 Market size and forecast
6.5.4 Latin America: market size and forecast
6.5.5 Middle East market size and forecast
6.5.6 Africa: market size and forecast
CHAPTER 7 GLOBALASTHMA AND COPD DRUGS PIPELINE -2015
CHAPTER 8 COMPANY PROFILES
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company overview
8.1.2 Operating business segments
8.1.3 Business performance
8.1.4 Key strategic moves & developments
8.2 Merck & Co., Inc.
8.2.1 Company overview
8.2.2 Operating business segments
8.2.3 Business performance
8.2.4 Key strategic moves & developments
8.3 GlaxoSmithKline PLC.
8.3.1 Company overview
8.3.2 Operating business segments
8.3.3 Business performance
8.3.4 Key strategic moves & developments
8.4 Novartis AG
8.4.1 Company overview
8.4.2 Operating business segments
8.4.3 Business performance
8.4.4 Key strategic moves & developments
8.5 AstraZeneca
8.5.1 Company overview
8.5.2 Operating business segments
8.5.3 Business performance
8.5.4 Key strategic moves & developments
8.6 F. Hoffmann-La Roche Ltd
8.6.1 Company overview
8.6.2 Operating business segments
8.6.3 Business performance
8.6.4 Key strategic moves & developments
8.7 Teva Pharmaceutical Industries Ltd.
8.7.1 Company overview
8.7.2 Operating business segments
8.7.3 Business performance
8.7.4 Key strategic moves & developments
8.8 Vectura Group plc.
8.8.1 Company overview
8.8.2 Operating business segments
8.8.3 Business performance
8.8.4 Key strategic moves & developments
8.9 Pfizer, Inc.
8.9.1 Company overview
8.9.2 Operating business segments
8.9.3 Business performance
8.9.4 Key strategic moves & developments
8.10 Abbott Laboratories
8.10.1 Company overview
8.10.2 Operating business segments
8.10.3 Business performance
8.10.4 Key strategic moves & developments